PRESS-RELEASE ·Filed Jul 9, 2026

NBIX

Neurocrine Biosciences, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Routine scheduling press release with no trading implications. No material financial data or guidance changes are contained in this filing. The actual Q2 2026 earnings results will be released on July 30, 2026 — monitor that event for financial performance and guidance updates.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
NBIX ▼ -7.74% at T+20d
NEUTRAL call ✗ call lost -7.74% · α vs SPY -10.16% · entry $177.11 → $163.41
Next anchor: T+60d due 11h ago
Latest observation: T+58 -55.42% FF3 residual α
Entry anchored
Jul 9, 03:59 PM ET
via exchange tick
T+1d
-1.71%
call -1.71% · α -0.92%
$174.09
settled 3mo ago
T+5d
-3.14%
call -3.14% · α -2.58%
$171.55
settled 3mo ago
T+20d
-7.74%
call -7.74% · α -10.16%
$163.41
settled 8w ago
T+60d
—
call — · α —
—
due 11h ago

Price Chart

Loading chart...

Executive Summary

Neurocrine Biosciences announced the schedule for its Q2 2026 earnings release and conference call on July 30, 2026, with no financial results or material disclosures. This is a routine scheduling announcement with no market-moving information.

Key Financial Metrics

Revenue
$877.8M

Key Facts

  • Q2 2026 earnings press release scheduled for July 30, 2026 at 4:00 p.m. ET
  • Conference call and webcast to follow at 4:30 p.m. ET
  • No financial results, guidance, or operational updates provided
  • This is a routine scheduling press release with no material financial content

Financial Impact

No financial impact; scheduling announcement only

Risk Factors

  • No new risks identified; this is a forward-looking scheduling announcement

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (37 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302822071
17 reports for NBIX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +27.40%Apr 6, 2026
Filters
Rows
Reports for NBIX — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$149.50 $139.49▼ −6.70%▼ −9.26%$143.18 (−4.23%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$174.10 $170.88▼ −1.85%▼ −1.06%$143.18 (−17.76%)
Jul 9, 2026
12w ago
Press Release
NEUTRAL ★ 2/10
$177.11 $171.55▼ −3.14%▼ −2.58%$143.18 (−19.16%)
Jun 9, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$160.86 $156.42▼ −2.76%▼ −6.19%$143.18 (−10.99%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$163.88 $159.76▼ −2.51%▼ −3.08%$143.18 (−12.63%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (38h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 9, 2026